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Tumor Vasculature as a Therapeutic Target in Non-small
Cell Lung Cancer
Jair Bar, MD, PhD, and Glenwood D. Goss, MD, FCPSA, FRCPC
Introduction: We aim to describe the molecular mechanisms rele-
vant to angiogenesis inhibition and to critically evaluate the current
evidence for the use of angiogenic inhibitors (AIs) in the treatment
of non-small cell lung cancer (NSCLC).
Methods: The literature on the basic concepts of tumor angiogen-
esis is reviewed. Published articles and major lung cancer confer-
ence abstracts were screened for reports on the use of AI in NSCLC
patients and the National Institutes of Health clinical trials database
was searched for relevant ongoing studies.
Results: We delineate in this review the molecular and cellular
aspects of angiogenesis and vasculogenesis and outline the rele-
vance of these to lung cancer. Clinical studies of AIs in NSCLC
reported to date as well ongoing studies are summarized. Major
issues discussed include the choice of the right molecular target;
characteristics of various tyrosine kinase inhibitors; potential draw-
backs and concerns regarding the application of AIs in clinical
practice, and major unanswered questions and future directions.
Conclusions: AIs have antitumor activity in NSCLC and have
become part of the standard of care for patients with advanced
nonsquamous cell carcinoma. Unfortunately, the gains have been
modest and robust predictive biomarkers are urgently needed. Clin-
ical trials to date have validated the tumor vasculature as a legitimate
target, and as our understanding of the biology of tumor angiogen-
esis increases, exciting new therapeutic approaches are being ex-
plored.
Key Words: Angiogenic inhibitors, Non-small cell lung cancer,
Vascular endothelial growth factor, Tyrosine kinase inhibitors, Pre-
dictive biomarkers.
(J Thorac Oncol. 2012;7: 609–620)
Lung Cancer Angiogenesis
As a malignant growth exceeds the size of a few 100
m, nutrient diffusion becomes a growth-limiting factor.
Hypoxia and cancer-specific genetic abnormalities, mainly by
up-regulation of the hypoxia inducible factors, drive the
secretion of proangiogenic factors (e.g., vascular endothelial
growth factor [VEGF], basic fibroblast growth factor [FGF])
and the suppression of antiangiogenic factors (e.g., throm-
bospondin, endostatin), making the tumor microenvironment
proangiogenic. New blood vessels are formed, and existing
blood vessels are modified to provide blood supply to the
tumor. The sprouting of blood vessels from existing blood
vessels is called angiogenesis, whereas production of de novo
blood vessels is termed vasculogenesis. Both processes are
controlled by the counteracting effects of proangiogenic and
antiangiogenic factors. The tipping of the balance toward a
proangiogenic state, “the angiogenic switch,” is essential for
cancer progression. Unlike in physiological angiogenesis,
reperfusion and reoxygenation do not turn off cancer angio-
genesis, which is driven by tumor-secreted factors. Tumoral
angiogenesis was suggested as a therapeutic target 40 years
ago.1 However, only recently have angiogenesis inhibitors
been added to the available therapeutic armamentarium
against colon, breast, kidney, brain, and other cancers. Figure
1 depicts some of the major cellular and molecular factors in
cancer angiogenesis.
Histological evidence of enhanced angiogenesis in lung
tumors has been associated with a poor prognosis2,3 and
levels of various molecular mediators of the angiogenic
switch correlate with poor clinical outcome.4 The clinical
importance of angiogenesis inhibition in the treatment of
non-small cell lung cancer (NSCLC) has been demonstrated.5
However, it should be noted that a subgroup of NSCLC with
nonangiogenic pattern has also been described.6–8 These
tumors seem to co-opt existing blood and lymphatic vessels
rather than induce angiogenesis, and importantly have a
worse prognosis than their angiogenic counterparts. Hence, it
is unlikely that antiangiogenic treatments would be effective
for all lung cancer patients.
Major Molecular Mediators of Angiogenesis
Angiogenesis involves multiple cellular events and
many interactions among a variety of cell types. A large
number of molecules have been identified as modulators of
processes required for the enhancement of tumor perfusion. A
selected number will be mentioned below. For a recent
comprehensive review of molecular and cellular mediators,
see Ref. 9.
Vascular endothelial growth factor
Initially named vascular permeability factor, VEGF is a
glycoprotein that induces endothelial permeability and func-
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tions as a mitogenic and survival factor of endothelial cells.10
There are five family members in mammalian cells, VEGF-A
to -D and placental growth factor (PlGF). VEGF-A is known
also as VEGF, and we will use this term in this review. Five
isoforms of VEGF exist (VEGF121, VEGF145, VEGF165,
VEGF189, and VEGF206), differing by their affinity to the
extracellular matrix and in their clinical importance.11
VEGF binds Flt-1/VEGFR-1 and Flk-1/VEGFR-2/
KDR (kinase domain region), tyrosine kinase receptors, ex-
pressed by vascular endothelial cells, and by tumor cells and
some epithelial cells. VEGFR-2 is a dominant positive reg-
ulator of the vascular system. VEGFR-1 has a higher binding
affinity for VEGF than VEGFR-2 but lower kinase activity
and no mitogenic response. VEGFR-1 knock-out mice die of
overgrowth of endothelial progenitors.12 In contrast, mice
expressing a kinase-dead-VEGFR-1 develop normally, sug-
gesting that this protein is a required negative regulator of the
VEGF pathway, acting by sequestering ligand molecules.13
However, other models demonstrate VEGFR-1 to be a posi-
tive angiogenesis regulator,14 important in the recruitment of
circulating endothelial precursors15 and of inflammatory
cells, which in turn secrete proangiogenic mediators. In
addition, VEGFR-1 and VEGFR-2 cross-phosphorylate and
activate each other when activated by PlGF and VEGF,
respectively. The precise role of VEGFR-1 might be context
dependant.
Much less is known about the other members of the
VEGF pathway. VEGF-C and VEGF-D mainly regulate
lymph vessel formation through activation of VEGFR-3,16
although VEGFR-3 activity also seems to be required for
blood vessel angiogenesis.17
VEGFR-2 ligand binding causes receptor dimerization,
tyrosine phosphorylation, and activation of downstream sig-
naling. Neuropilin-1 is a modulating coreceptor of VEGFR-2
activity. High neuropilin-1 mRNA levels in NSCLC tumors
were found to be an independent negative prognostic factor.18
Another modulator of VEGFR is vascular endothelial-cad-
herin, which forms a complex with VEGFR-2, -catenin, and
PI3K and is required for the transmission of the survival
signal.19 The VEGF pathway is a major regulator of angio-
genesis, cross-talking with other growth factor signaling
pathways, some of which are mentioned below.
Platelet-derived growth factor
The platelet-derived growth factor (PDGF) ligands,
secreted by tumor cells and endothelial cells, activate PDGF
receptors, expressed by pericytes, thus recruiting them to
developing vessels. Pericytes have a supportive and modu-
lating role for blood vessels. Abnormal pericyte vessel cov-
erage in PDGF-B null mice results in vessel dilatation,
leakage, and hemorrhage.20 The PDGF pathway is also in-
volved in cancer-associated fibroblasts signaling and in au-
tocrine cancer stimulation.9 The importance of the PDGF
pathway in NSCLC is supported by the correlation found
between high tumor PDGF expression levels and poor prog-
nosis.21 Preclinical studies indicated enhanced antiangiogenic
efficacy of a combined inhibition of VEGFR and PDGFR.22
Notably, in some cases, platelet-derived endothelial cell
growth factor, which is the enzyme thymidine phosphorylase,
produced by the TYMP gene, is mistakenly referred to as
PDGF.
Angiopoietin (Ang)
The angiopoietin family is composed of four ligands
that bind the Tie-2 tyrosine kinase receptor. Ang-1 and Ang-4
function mostly as positive regulators, whereas Ang-2 and
Ang-3 are mostly antiangiogenic. However, these roles are
context dependent. Ang-2 antagonizes the Ang-1-dependent
recruitment of pericytes to new blood vessels, thus preventing
their stabilization. Ang-2 knockout mice have defects in adult
vascular sprouting, suggesting that destabilization of the
vessel structure is required for angiogenesis to progress.
Ang-2 seems to have a proangiogenic role when VEGF is
abundant but an antiangiogenic role when VEGF levels are
low.23 High tumor Ang-2 expression has negative prognostic
implications in lung cancer patients, especially when VEGF
expression is high.24 Ang-1 has a negative role in tumor
angiogenesis, probably secondary to enhanced pericyte vessel
coverage and reduced vessel permeability. The resultant ves-
sels do not allow extravasation of plasma proteins and the
microenvironment formed is less proangiogenic.
Endogenous antiangiogenic factors
Potent antiangiogenic factors can be produced endog-
enously by cleavage of other proteins. For example, angiosta-
tin, a potent angiogenesis inhibitor, is the cleavage product of
plasminogen, a component of the coagulation control mech-
anism. Macrophage-derived methalloelastase (MMP-12) is
thought to be responsible for the in vivo conversion of
plasminogen to angiostatin.25 Thus, tumor-infiltrating macro-
phages may determine the production of antiangiogenic fac-
tors. In addition, cancer cells may secrete enzymes required
for the production of angiostatin. Endostatin is an antiangio-
genic factor that is a fragment of collagen-XVIII. Additional
potent antiangiogenic factors are produced by the cleavage of
common proteins,26 suggesting that the tight control of an-
giogenesis requires reserves of antiangiogenic factors ready
for rapid mobilization. Thrombospondin-1 is another endog-
enous angiogenic inhibitor (AI), mimetics of which are in
early clinical trials.27
Cell-cell adhesion molecules
The formation of new blood vessels requires interac-
tions among endothelial cells, pericytes, smooth muscle cells,
inflammatory cells, and epithelial cells and involves cell-cell
adhesion molecules. Intercellular adhesion molecule 1
(ICAM-1) is a transmembrane protein involved in endothelial
cell survival and migration. Plasma ICAM levels were found
to be prognostic in a study of lung cancer patients treated with
an anti-VEGF antibody.28 N-Cadherin is another cell–cell
interaction molecule being evaluated currently as a target for
antiangiogenic treatment.29
Growth factors and cytokines
Basic FGF is a potent angiogenic factor that stimulates
the proliferation and migration of endothelial cells and the
production of matrix metalloproteases (MMPs). Importantly,
resistance to VEGFR inhibition can arise from up-regulation
of FGF signaling.30 Cytokines also modulate angiogenesis,
conceivably by regulating leukocyte recruitment. Interleukin
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(IL)-8, IL-12,31 and transforming growth factor  are exam-
ples of cytokines found to correlate with lung cancer angio-
genesis. These and other cytokines are being investigated as
predictive factors of efficacy or as therapeutic targets.32,33
Agents Targeting Angiogenesis in Lung Cancer
Targeting the VEGF ligand
Bevacizumab (“Avastin,” Roche, Basel, Switzerland) is
a monoclonal antibody directed against the VEGF ligand
(VEGF-A specific). It was the first bonafide AI to be ap-
proved for cancer treatment, initially in colorectal carcinoma.
Single agent bevacuzumab improved progression-free sur-
vival (PFS) in a few trials but seemed inefficient by itself in
most cases, and its administration to NSCLC patients in
combination with chemotherapy was tested. A phase II study
comparing carboplatin and paclitaxel with or without bevaci-
zumab demonstrated improved PFS and a trend of improved
overall survival (OS) in the experimental arm34 and led to a
phase III trial. Because of cases of fatal pulmonary hemor-
rhages in squamous cell carcinoma patients in the phase II
trial, bevacizumab was henceforth mostly tested in nonsqua-
mous cell lung cancers and is currently approved only for
nonsquamous cell lung cancers.
The Eastern Cooperative Oncology Group evaluated
bevacizumab in a phase III study of 878 advanced nonsqua-
mous-cell cancer patients (ECOG 4599) randomized to re-
ceive paclitaxel and carboplatin with or without bevaci-
zumab. There was a statistically significant increase in
median survival from 10.3 to 12.3 months favoring the
bevacizumab arm.5 This trial lead to the approval of bevaci-
zumab for advanced nonsquamous NSCLC as first line reg-
imen. Bevacizumab treatment was also evaluated in combi-
nation with cisplatin and gemcitabine (the AVAiL study) in
1050 advanced NSCLC patients and was shown to signifi-
cantly increase PFS from 6.1 to 6.5 or 6.7 months (in the high
and low dose groups, respectively), thus meeting its primary
end point. No difference in OS was found in this study.35 The
reason for the difference in the results of the AVAiL and
the E4599 is not known but could be due to differences in the
patient cohorts, the inferior activity of paclitaxel and carbo-
platin versus cisplatin and gemcitabine, and the in vitro data
supporting synergy between taxanes and bevacizumab.36 In
the BeTa-lung phase III trial, bevacizumab was added to
erlotinib (“Tarceva,” Roche, Basel, Switzerland) as second-
line treatment. PFS was improved from 1.7 to 3.4 months, but
only a trend toward survival benefit, the trial’s primary end
point, was shown.37 Recently, two studies of bevacizumab
combined with chemoradiotherapy have reported an alarm-
ingly high rate of tracheoesophageal fistula formation.38
However, another study has reported acceptable toxicity39
and studies are ongoing. As with many other agents that
demonstrate activity in the advanced setting, bevacizumab is
also being evaluated in the adjuvant setting, in the random-
ized phase III study ECOG 1505 (NCT00324805). Phase III
studies testing AIs are summarized in Table 1 and selected
phase I and II studies are presented in Table 2.
VEGF-trap (“Aflibercept,” NSC-724770, AVE0005,
Regeneron, Inc., Sanofi-Aventis, Paris, France) is a novel
agent designed to function similarly to bevacizumab. VEGF-
trap is a recombinant protein, similar to the extracellular-
ligand binding domains of VEGFR-1 and 2. It binds all
VEGF isoforms and binds VEGF and VEGF-B with a higher
affinity than bevacizumab. A phase II study reported some
responses in heavily pretreated patients,61 leading to an on-
going phase III trial, testing the addition of aflibercept to
docetaxel as a second-line treatment (NCT00532155).
Targeting the VEGF receptors
Fueled by the success of bevacizumab in advanced
NSCLC and by evidence of efficacy of VEGFR inhibitors in
other malignancies, much effort have been invested in testing
VEGFR inhibitors in NSCLC. Most appealing is the possi-
bility of inhibiting several of the pathways involved in an-
giognesis simultaneously. This can be achieved by tyrosine
kinase inhibitors (TKIs), which frequently target multiple
tyrosine kinase receptors. Most of them co-target the VEG-
FRs, PDGFRs, and c-Kit, related to their common split-
kinase structure. TKIs have the convenience of oral admin-
istration. Their short half-life necessitates daily dosing but
facilitates the control of reversible toxicities. Bioavailablilty,
pharmacokinetic, and pharmacodynamic properties contrib-
ute to differences among the TKIs. Importantly, multikinase
inhibition might be antagonistic in some cases. For example,
if inhibiting VEGFR-1 would have in tumors a similar effect
as knocking it out in mice, enhanced angiogenesis might be
expected. Most TKIs, including some claiming high specific-
ity, actually inhibit a significant number of kinases, as dem-
onstrated in an in vitro study testing the affect of 38 TKIs on
a set of 317 kinases.62 Because of the technical challenges
inherent in the assessment of kinase inhibition, indirect com-
parisons of different TKIs, and TKI-defined target claims,
should be evaluated cautiously. This group of agents includes
most of AI agents tested in clinical trials today (Table 1).
Below, we discuss aspects of some of these TKIs.
Sunitinib (SU11248, Pfizer, New York, NY) was de-
veloped as an oral inhibitor of VEGFR-1–3, PDGFR- and ,
and c-Kit receptor. More extensive molecular analysis dem-
onstrates it to be one of the most promiscuous TKIs, inhib-
iting 18% of the 317 tested kinases.62 An approved drug for
the treatment of gastrointestinal stromal tumor and metastatic
renal cell carcinoma (RCCa), it is being tested now as a
treatment for NSCLC. Sorafenib (Nexavar, Bayer, Germany)
is another TKI, also approved as a treatment for RCCa and
for hepatocellular carcinoma. It was designed to target Raf
kinase but found to inhibit also VEGFR-1–3, PDGFR, RET,
KIT, and FLT-3. A phase III trial comparing chemotherapy
with and without sorafenib (ESCAPE trial), closed after it
failed to show any benefit with the sorafenib combination.63
Importantly, in the squamous-cell cancer subgroup of patients
(N  219), sorafenib-treated patients’ survival was reduced
from 13.7 to 8.9 months. This is reminiscent of the squa-
mous-cell specific detrimental effect seen with bevacizumab
and also noted with Motesanib (AMG706, Amgen, CA)
another VEGFR/PDGFR TKI. A detrimental effect of some
AI drugs in a subset of patients does not indicate necessarily
that this AI or the whole class should be abandoned; rather, it
stress the need for biomarkers that will target those drugs to
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the patients most likely to benefit from it and prevent its use
in patients that would be harmed by it. Cediranib (AZD2171,
“RECENTIN,” AstraZeneca, London, UK), another oral in-
hibitor of VEGFR-1–3, PDGFR-, and c-Kit receptor, is an
example of this point. A phase II–III trial (BR.24, NCIC-
CTG) examined the addition of this agent to a carboplatin and
paclitaxel regimen.42 Significant toxicities required a reduc-
tion of the cediranib dose (from 45 to 30 mg daily). Further-
more, although the death rate was similar in the two arms of
the study, a higher rate of treatment-related death was noted
in the cediranib arm. However, the response rate increased
from 16 to 38% and the hazard ratio for progression-free
survival was 0.77 in favor of the cediranib arm42 (in the 30
mg cohort, the median progression-free survival was 5.6
months versus 5 months; in the 45 mg cohort, 6.05 versus
5.45 months in the cediranib and placebo arms, respectively).
A positive impact of cediranib was seen regardless of gender,
histology, or smoking status. Baseline weight loss of more
than 5% and hypoalbuminemia predicted increased toxicity
for patients receiving cediranib. This led to the initiation of a
second trial similar in design, using a lower dose (20 mg) of
cediranib, and excluding patients with a weight loss of more
than 5% (NCIC-CTG BR.29). Using this approach, the in-
vestigators hope to sustain the positive impact of cediranib
while reducing toxicity.
An example of a non-TKI that targets the VEGFR is
Ramucirumab (Eli Lilly, IN), a novel antibody directed
against VEGFR-2, unlike bevacizumab that targets the VEGF
ligand.58 Directed against the extracellular component of the
receptor, its mechanism of inhibition is different than the
TKIs, thus in theory both might be applied in concert.
Targeting the EGFR and additional receptors
Vandetanib (ZD6474, “Zactima,” AstraZeneca) is an
oral inhibitor of VEGFR-2, 3, Ret kinase, and EGFR, con-
ceived with the idea that blocking both angiogenesis and
tumor cell proliferation would be synergistic. This drug
showed promising activity in advanced NSCLC in several
phase II trials, leading to four recently reported phase III
studies. None of these trials demonstrated an improvement in
survival for patients receiving vandetanib, although the ZO-
DIAC trial met its end point of improved PFS (Table 1). The
failure of vandetanib to improve OS might be related to the
fact that it inhibits EGFR about 10-fold less than it does
VEGFR264 and thus might not actually target both intended
pathways. XL 647 (Exelixis, CA) is another oral TKI that
targets the VEGFR and EGFR pathways, and inhibits Her2
and EphB4, that was tested in NSCLC patients, demonstrat-
ing moderate activity in patients harboring EGFR muta-
tions.65 Brivanib (BMS-582664, Brisol-Myers Squibb, NY) is
a TKI targeting FGFR and EGFR, thus targeting both angio-
genesis and tumor cell proliferation, currently in phase II
trials (NCT00633789).
Combining different agents is another manner of inhib-
iting both the EGFR and the VEGFR pathways. Sorafenib
addition to erlotinib treatment did not improve disease-free
survival although disease control rate was better (D. Spigel,
personal communication, February 2010). Cetuximab with
bevacizumab and chemotherapy66 is currently being evalu-
ated (NCT00946712), bevacizumab being given to all eligi-
ble patients, and randomization done between addition of
cetuximab or not. It should be noted that addition of cetux-
imab to a bevacizumab-chemotherapy regimen worsened out-
comes of colorectal cancer patients in two recent trials.67,68
Targeting existing blood vessels (vascular
disrupting agents)
Unlike AIs that aim to prevent the sprouting of vessels
or the production of new ones, vascular disrupting agents
(VDA) target existing blood vessels. VDA can bring about a
collapse of the tumor’s vascular supply and massive necrosis
within hours. Besides the title, various VDA have little in
common, embracing a range of mechanisms of action. There
are antibodies or peptides that target toxins to tumor-vascu-
lature-specific epitopes, tubulin-binding molecules that target
dividing cells and others that are activators of cytokine
production. A characteristic observation in studies of VDA is
the viable rim of live tumor cells, the culprit of repopulation
that remains around an area of central necrosis.69 For this
reason, VDAs are considered best combined with chemother-
apy, radiotherapy, AIs, or other agents that would disrupt this
viable rim. Combretastatin A4 phosphate (CA4P, “fos-
bretabulin,” OXiGENE, CA) inhibits microtubule assembly,
whereas 5,6-dimethylxantlenone-4-acetic acid (DMXAA,
ASA404, vadimezan) functions through a different mecha-
nism, partly by activating interferon-. Originally isolated
from the South African willow tree Combretum caffrum,
these agents block tumor blood flow rapidly by causing
vasoconstriction of tumor-feeding arterioles, or by endothe-
lial cell apoptosis.70 A promising randomized phase II study
with ASA404 has lead to two phase III trials, both of them
recently reported as negative.50,51 CA4P is currently in phase
II studies.71 ABT-751 is a novel antimicrotubule agent also
defined as VDA. A phase I–II of this agent in combination
with pemetrexed was recently reported with interesting evi-
dence of activity in squamous cell carcinoma patients.72
Targeting angiogenesis using chemotherapy
In in vivo models, chemotherapy given at doses much
lower than the maximal tolerated dose, but on a continuous
basis (metronomic treatment), has a marked antiangiogenic
effect.73 Ongoing trials are evaluating this strategy. Some
chemotherapy agents targeting the cytoskeleton are potent
endothelial cells toxins, e.g., paclitaxel and docetaxel.74,75
Furthermore, paclitaxel and docetaxel cause a reduction of
interstitial fluid pressure (IFP) by killing tumor cells, thus
allowing better tissue perfusion and better drug delivery.76
Targeting other angiogenic mechanisms
A recombinant version of endostatin, an endogenous
antiangiogenic factor discussed above, was evaluated in 42
patients with neuroendocrine tumors with no documented
responses.77 Endostar, (YH-16, Simcere, China) is a recom-
binant human endostatin modified by the addition of nine
amino acids, thus simplifying the purification process and
improving stability. In a study of 493 advanced NSCLC
patients, addition of endostatin to chemotherapy led to in-
creased time to progression, from 3.6 to 6.3 months.48 Re-
cently approved in China for NSCLC patients, it is being
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tested in various settings including two phase III trials in
metastatic disease.
N-Cadherin is a cell-cell adhesion molecule, expressed
by endothelial cells and some cancer cells. ADH-1 is an
inhibitor of N-Cadherin (Exherin, Adherex, Durham, NC)
that was recently tested in phase I–II studies that included
NSCLC patients (NCT00265057, NCT00264433). Thalido-
mide has an antiangiogenic activity that is poorly understood
and may act indirectly through its immunomodulatory ef-
fects. A negative phase III study testing its role in NSCLC
was recently published.52
Targeting tumor vasculature-specific proteins is an ad-
ditional approach which seems appealing as a therapeutic
strategy. Tumor-blood-vessel-specific proteins and phospho-
lipids have been identified. One of these is phosphatidylser-
ine, normally found only in the inner lipid leaflet of the cell
membrane but translocates to the outer leaflet in tumor
vasculature. It is currently targeted in the clinic by a novel
specific antibody (bavituximab, Peregrine, CA).78
Insight from Studies Using AIs in Lung Cancer
Resistant angiogenesis
Although many AIs show promising responses and PFS
improvements in NSCLC patients, almost none bring about
prolongation of survival. The reasons for this phenomenon
are not known. A relevant observation might be rebound
angiogenesis, observed in mice studies where the VEGF
pathway was effectively attenuated.30 In these models, alter-
native angiogenic mechanisms are up-regulated, including
induction of FGF family members, angiopoietins, and vessel
co-option, possibly triggered by hypoxia in tumors subjected
to VEGF inhibition.79 Indeed, up-regulation of one of several
alternative angiogenic pathways has been demonstrated in
human lung cancers.80 Another important finding in models
of VEGF-dependent tumor growth treated with VEGF inhib-
itors is increased invasiveness of tumors that thrive in these
conditions.30,81 This could be secondary to hypoxia-induced
activation of the hepatocyte growth factor-Met pathway,82
urokinase-type plasminogen activator,83 or other survival
pathways. Furthermore, hypoxia may select for tumor cells
with an aggressiveness phenotype, e.g., those with loss of
p5384 or other genetic events.85 Two recent studies in mice
models indicate a risk of enhanced metastatic spread as a
result of AI treatment.86,87 Using VEGF pathway inhibition as
a cancer therapeutic strategy, requires further understanding
about cancer escape and resistance mechanisms.
The requirement for a continuous treatment
The importance of treatment schedules of AIs is cur-
rently not clear. Rebound accelerated tumor growth is seen on
discontinuation of bevacizumab treatment of metastatic colo-
rectal cancer88 and in patients with glioblastoma multiforme
during drug holiday of a VEGFR inhibitor.89 Sunitinib and
axitinib treatment breaks result in increase tumor perfusion
and proliferation.90 In a retrospective comparison of two
cohorts of a sunitinib phase II study, more responses were
seen in a noncontinuous, higher dose treatment, but longer
survival was observed in the cohort treated continuously,91
supporting the principle of daily administration of AI drugs.
Regarding the length of treatment, current practice with most
AIs is continuous treatment till progression. Supportive of
this, maintenance bevacizumab prolonged PFS in a recent
phase III trial of ovarian, peritoneal, and fallopian carcino-
mas.92 When combined with chemotherapy, it is not known
whether AIs should be continued beyond progression. We are
not aware of any studies designed to answer this question.
Combining AI treatments with chemotherapy
The only trial where an AI prolonged the life of
NSCLC patients involved administering bevacizumab with
chemotherapy. However, when an AI agent is given concur-
rently with a cytotoxic agent, antagonism is expected, be-
cause damaging the tumor’s blood supply should hinder
delivery of the cytotoxic agents. A possible explanation for
the apparently unexpected synergism observed clinically was
suggested by Jain and others regarding the IFP of tumors.93
The increased permeability typical of tumor vessels results in
extravasation of macromolecules and fluid to the extravascu-
lar compartment and increased IFP. This increased IFP re-
duces vascular flow and drug delivery. AIs cause a rapid
normalization of tumor vasculature, reducing their permea-
bility and the IFP. Thus, before elimination of the vessels that
perfuse a tumor, a window of opportunity might exist when
tumor perfusion and drug delivery is increased.94 IFP is
reduced after treatment with anti-VEGF antibody,93 with a
VDA,95 and with sunitinib,96 cediranib89 and pazopanib (Vot-
rient, GlaxoSmithKlin, UK).97 However, improved tumor
perfusion after such treatments remains a theoretical consid-
eration and to date has not been consistently demonstrated by
perfusion studies in humans. In contrast, axitinib decreased
tumor exposure to concomitantly given cyclophosphamide,98
and sunitinib treatment only enhanced day 3 diffusion param-
eters and not tumor perfusion.99 On the basis of those obser-
vations, it can be speculated that an AI-drug holiday before
chemotherapy administration might enhance chemotherapy
delivery and treatment efficacy. However, AI and chemother-
apy synergism might be secondary to enhanced killing of
tumor endothelial cells,4,75,98 suggesting they should be given
concurrently. The requirement for an AI-drug holiday is
being investigated in a phase I-II trial combining axitinib with
cisplatin/pemetrexed (NCT00768755).
Taxanes were shown to mobilize bone marrow-derived
circulating endothelial progenitor cells (CEPs) that colonize
tumors and allow for regeneration of tumor vasculature after
treatment.36 Blocking the VEGF pathway prevents the CEPs
surge and might be basis for chemotherapy-AI synergism,
possibly limited to drugs that mobilize CEPs.
Evaluating response to AI treatments
An apparent class effect of AI treatments is tumor
cavitation, seen in 24% of treated tumors in one published
series.100 It seems plausible that assessing response solely
according to RECIST criteria might misclassify cavitating
tumors. An alternative single dimension measurement taking
cavitation size into account was recently proposed.100 Soft-
ware-assisted volumetric measurement is an alternative ap-
proach. The role of these novel response measurements needs
to be examined in large trials, comparing them to standard
RECIST criteria.
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Toxicities of AIs
Less than 1% of adult endothelial cells are actively
proliferating, suggesting that targeting endothelial prolifera-
tion would impact only tumor-activated endothelial cells and
wound healing and be devoid of significant side effects.
However, the toxicities seen with VEGFR inhibitors indicate
an unappreciated role of VEGF in microvessels and tissue
homeostasis. Further discussion of this topic is beyond the
scope of this review. Interestingly, some toxicities might be
useful as predictive markers of response to treatment.101
Predicting Response to AI Treatments
In light of the potentially significant toxicities and lack
of survival benefit in many of the AI trials, there is an urgent
need for predictive biomarkers. In an analysis of the E4599
trial, VEGF plasma levels were predictive of response to
bevacizumab but not predictive of a survival benefit.28 In
contrast, VEGF plasma levels were negatively correlated
with PFS in patients treated with vandetanib,102 and a greater
increase in VEGF plasma levels with vandetanib treatment
predicted worse outcome.32 PlGF elevation showed a trend to
be predictive of response to motesanib.103 Polymorphisms in
the VEGF gene, and in the ICAM-1 and WNK1 genes were
found to correlate with bevacizumab-related improved sur-
vival.104 An increase in ICAM-1 levels with treatment was
associated with a better PFS in vandetanib-treated NSCLC
patients.32 Analysis of E4599 samples revealed improved
PFS with bevacizumab for patients with low baseline levels
of ICAM-1 and improved OS with bevacizumab for patients
with stable levels of E-selectin.28 Baseline levels of hepato-
cyte growth factor and of IL-12 were predictive of response
to pazopanib.33 Tumor mRNA levels of LDH-A, Glut-1, and
VEGFR-1 were found to predictive of response to the
VEGFR inhibitor PTK787/ZK 222584 in colorectal cancer
patients.105
In vivo measurements of patients’ tumor blood per-
fusion changes with initial doses of the antiangiogenic
agent are potential predictive markers. Magnetic resonance
imaging dynamic contrast enhancement measurements af-
ter 2 days of an oral antiangiogenic treatment were found
to correlate with patients’ drug exposure.106 As early as 24
hours after the first oral dose of an angiogenesis inhibitor,
a significant reduction of permeability and vessel size can
be demonstrated.89 The predictive power of these imaging
studies is yet to be validated.
Clinical characteristics might also be predictive. Fe-
male patients did not benefit from bevacizumab in the
E4599,107 whereas an opposite trend was seen in the AVaiL
trial35 and in a phase II vandetanib trial32 (a result not
reproduced in the phase III vandetanib trial43). Adenocar-
cinoma patients had a clear benefit from bevacizumab, a
result that could not be demonstrated for other nonsqua-
mous histologies.108 Recently, antiangiogenesis-induced
arterial hypertension was found to correlate with clinical
response and outcome in various tumors.109 –111 Retrospec-
tive analysis of the E4599 NSCLC trial demonstrates that
HTN induced by bevacizumab correlates with a signifi-
cantly improved OS101 but conflicting results have been
reported in colorectal cancer.112 So far, none of the above
mentioned candidate predictive biomarkers have been val-
idated prospectively.
Summary and Future Directions
Angiogenesis inhibitors have obvious antitumor activ-
ity in NSCLC and bevacizumab has become part of the
standard of care for patients with advanced nonsquamous cell
carcinoma. Unfortunately, to date, the gains have been mod-
est. As we learn more about angiogenesis, the complexity of
the biology becomes apparent (Figure 1) and the number of
unanswered questions increase (Table 3). As seen in many
areas of medicine in the past, some of the answers may be
surprisingly simple. New and exciting areas of research
include elucidating the role of CEPs, tumor-vasculature spe-
cific molecules that allow their specific targeting, novel
signaling pathways involved in angiogenesis and in vivo
real-life imaging of the vasculature and tumor cell prolifera-
tion. These developments and others are eagerly awaited. In
conclusion, the tumor vasculature remains an important area
of anticancer research. Better understanding of the biology
FIGURE 1. Vascular endothelial growth factor (VEGF) secre-
tion by tumor cells is induced by tumor hypoxia and onco-
gene signaling.4 VEGF acts mainly on endothelial cells, in-
ducing angiogenesis and a hyperpermeable state. Tumor
endothelial cells are one of the sources of platelet-derived
growth factor, which recruit pericytes to the vessels’ enve-
lope. N-Cadherin (N-Cad) physically connects endothelial
cells and pericytes.29 Plasma proteins such as fibrinogen and
fibronectin leak through the abnormal tumor vessels, con-
tributing to the proangiogenic microenvironment and to the
enhanced interstitial fluid pressure (IFP) typical of tumors.94
Tumor-associated macrophages are a subtype of macro-
phages that invade cancer stroma and secrete MMP9, lead-
ing to release of extracellular matrix-associated VEGF113;
these cells are also capable of promoting the formation of
antiangiogenic factors such as angiostatin.25 Circulating en-
dothelial progenitors (CEP) are putative bone marrow-de-
rived cells that home to tumor sites and might be a major
contributor to the newly formed blood vessels.69 This
scheme represents a partial view of the major players in-
volved in cancer angiogenesis.
Bar and Goss Journal of Thoracic Oncology • Volume 7, Number 3, March 2012
Copyright © 2012 by the International Association for the Study of Lung Cancer616
and trials with angiogenesis inhibitors has already yielded
positive results for NSCLC patients. Ongoing study of this
exciting target is imperative.
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